The effects of intracranial injection of three beta (3)-adrenoceptor agonis
ts, sodium-4-[-2[-2-hydroxy-2-(-3-chloro-phenyl)ethylamino]propyl]phenoxyac
etate (BRL 37344), 2-hydroxy-5(2-((2-hydroxy-3-(4-((1-methyl-4-trifluoromet
hyl)1H-imidazole-2-yl)-phenoxy)propyl)amino)ethoxy)-benzamide monomethane s
ulfonate) (+/-)-CGP12177A) and the pro-drug RS-N-(7-carbethoxymethoxyl 1,2,
3,4-tetrahydronaphth-2-yl)-2 hydroxy 2-(3-chlorophenyl)ethanamine (SR58611A
), were examined on reinforcement of memory in day-old chicks. BRL37344 and
CGP12177 facilitated memory, whereas SR58611A had no effect. The dose-resp
onse relationships of the beta (3)-adrenoceptor agonists were challenged wi
th the selective beta (3)-adrenoceptor antagonist 3-(2-ethylphenoxy)-1-[(1S
)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) or th
e beta (2)-adrenoceptor antagonist (-)propranolol. BRL 37344 appeared to ac
t predominantly at beta (3)-adrenoceptors at low doses and at beta (2)-adre
noceptors at higher doses. Facilitation of labile into long-term storage by
beta (3)-adrenoceptor agonists appears to be a class action of these drugs
. (C) 2001 Elsevier Science B.V. All rights reserved.